公开(公告)号：US20070098743A1

公开(公告)日：2007-05-03

申请号：US10551103

申请日：2004-03-29

申请人： John Bell ,  Brian Lichty ,  David Stodjl

发明人： John Bell ,  Brian Lichty ,  David Stodjl

IPC分类号： A61K39/205 ,  C12N7/00 ,  C12N15/86

CPC分类号： C12N7/00 ,  A61K39/12 ,  A61K39/205 ,  A61K2039/522 ,  A61K2039/5254 ,  A61K2039/572 ,  A61K2039/585 ,  C07K14/005 ,  C07K2319/07 ,  C12N2760/20222 ,  C12N2760/20232 ,  C12N2760/20234 ,  C12N2760/20261

摘要： The present invention provides mutant viruses with a decreased ability to block nuclear transport of mRNA or protein in an infected cell which are attenuated in vivo. The mutant viruses of the present invention may also be capable of triggering the anti-viral systems of normal host cells while remaining sensitive to the effects of these systems. The present invention further provides for the use of the mutant viruses in a range of applications including, but not limited to, as therapeutics for the treatment of cancer and infections, as vaccines and adjuvants, as viral vectors, and as oncolytic and cytolytic agents for the selective lysis of malignant or infected cells.

摘要翻译： 本发明提供了在体内减毒的受感染细胞中阻断mRNA或蛋白质的核转运能力降低的突变病毒。 本发明的突变病毒还可能能够触发正常宿主细胞的抗病毒系统，同时对这些系统的作用保持敏感。 本发明还提供了在一系列应用中使用突变病毒，包括但不限于作为治疗癌症和感染的治疗剂，作为疫苗和佐剂，作为病毒载体，以及作为溶瘤和细胞溶解剂 选择性裂解恶性或感染细胞。